LIPELLA PHARMACEUTICALS, INC.

Address

5414 GUARINO RD
PITTSBURGH, PA, 15217-1919

Information

DUNS: 187190850
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Clinical Development of Tacrolimus for Hemorrhagic Cystitis

    Amount: $514,245.00

    ABSTRACT Hemorrhagic cystitis HC is an inflammatory illness marked by bleeding in the bladder and urinary pain HC is a complication of radiation therapy and chemotherapy used to treat cancers of th ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation

    Amount: $224,999.00

    DESCRIPTION provided by applicant This project entails the development of a novel dual component MRI contrast agent formulation for the detecting permeability in the luminal surface of the urinary ...

    STTRPhase I2015Department of Health and Human Services
  3. Preclinical Development of Tacrolimus for Radiation Cystitis

    Amount: $1,278,375.00

    DESCRIPTION provided by applicant This project entitied andquot Preclinical Development of Tracrolimus for Radiation Cystitisandquot will fund key experiments to advance the commercial developmen ...

    SBIRPhase II2015Department of Health and Human Services
  4. Preclinical Development of Tacrolimus for Radiation Cystitis

    Amount: $222,176.00

    DESCRIPTION (provided by applicant): This project, entitied Preclinical Development of Tracrolimus for Radiation Cystitis will fund key experiments to advance the commercial development of LP-10. LP ...

    SBIRPhase I2014Department of Health and Human Services
  5. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $741,288.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. L ...

    STTRPhase II2014Department of Health and Human Services
  6. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $741,288.00

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions L ...

    STTRPhase II2014Department of Health and Human Services
  7. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $999,282.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposom ...

    SBIRPhase II2011Department of Health and Human Services
  8. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SB ...

    SBIRPhase I2009Department of Health and Human Services
  9. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $740,688.00

    DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder sy ...

    STTRPhase I2009Department of Health and Human Services
  10. Intravesical Liposome Treatment for Interstitial Cystitis

    Amount: $750,000.00

    DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladd ...

    SBIRPhase II2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government